DT&CRO CO., Ltd. (KOSDAQ:383930)

Market Cap	31.07B
Revenue (ttm)	44.36B +76.7%
Net Income	4.17B
EPS	-95.20
Shares Out	12.78M
PE Ratio	7.44
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	231,481
Average Volume	95,783
Open	2,550.00
Previous Close	2,570.00
Day's Range	2,435.00 - 2,680.00
52-Week Range	2,250.00 - 9,370.00
Beta	2.64
RSI	42.22
Earnings Date	n/a

About DT&CRO CO.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. It conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin, South Korea.

• Industry: Commercial Physical and Biological Research
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 383930

Financial Performance

In 2024, DT&CRO CO.'s revenue was 35.97 billion, an increase of 35.30% compared to the previous year's 26.59 billion. Losses were -2.00 billion, -87.98% less than in 2023.